Infliximab (Remicade) and increased incidence of development of basal cell carcinoma
Gaines-Cardone, E.; Hale, E.K.
Journal of Drugs in Dermatology Jdd 11(5): 655-656
2012
ISSN/ISBN: 1545-9616 PMID: 22527438 Document Number: 13130
Immunosuppression is a known risk factor for the development of non-melanoma skin cancers (NMSC). Certain medications that induce immunosuppression, such as tumor necrosis factor-α (TNF-α) inhibitors, are being used more frequently. We report a case of a young, pregnant woman who was treated with infliximab for Crohn's disease, and subsequently experienced a rapid growth of two pre-existing basal cell carcinomas. As use of TNF-α inhibitors increases, it is important to closely monitor patients for the development of NMSC.
Document emailed within 1 workday
